

Hopes that BeyondSpring will blossom on Nasdaq listing

By The Pharma Letter – 2017-03-09

The level of investor interest in USA-based biopharma company BeyondSpring is about to become apparent with the company's listing on the Nasdaq stock market.

BeyondSpring will trade under the stock symbol Nasdaq: BYSI following its initial public offering on Thursday, when the company's chief executive Lan Huang rang the opening bell.

Potential investors will likely have been attracted by the progress of plinabulin, BeyondSpring's lead asset, being developed to treat both non-small cell lung cancer (NSCLC) and a common and potentially life-threatening adverse effect of chemotherapy with docetaxel.

BeyondSpring has advanced plinabulin into a global Phase III trial as a direct anticancer agent in NSCLC and is planning a Phase II/III study in neutropenia.

With headquarters in New York City and offices in China, BeyondSpring will be one of the few public companies in the biopharma space that has a unique business model with China.

The idea behind this highly-scalable business model is to integrate US and Chinese clinical resources to create maximum value for physicians, patients and other stakeholders.

Link to article:

<https://www.thepharmaletter.com/article/hopes-that-beyondspring-will-blossom-on-nasdaq-listing>